Equity Details
Price & Market Data
Price: $155.5
Daily Change: +$3.57 / 2.30%
Daily Range: $150.5 - $157.0
Market Cap: $6,216,204,288
Daily Volume: 87,173
Performance Metrics
1 Week: 0.75%
1 Month: -10.19%
3 Months: -12.08%
6 Months: 37.41%
1 Year: 150.9%
YTD: -2.76%
About Belite Bio, Inc (BLTE)
Financial overview of Belite Bio, Inc (BLTE). Current price: 155.5, daily change: +$3.57 / 2.30%. Market cap: 6,216,204,288. Performance YTD, 1-week, 1-month.
Company Details
Employees: 41
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.